Farhad Ravandi-Kashani, M.D. Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Farhad Ravandi, MD a distinguished professor of medicine at the University of Texas MD Anderson, delivered a captivating presentation on advancing disease assessment in AML patients at a recent conference. Professor Ravandi emphasized the significance of utilizing advanced tools and assays to detect residual leukemia, as emerging data strongly link any remaining leukemia cells to a heightened risk of relapse and poorer outcomes.
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
The conference proved highly informative, showcasing cutting-edge research, including the promising potential of Menin inhibitors, a novel and thrilling development in the field.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content